A Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Patient-Initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes

Trial Profile

A Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Patient-Initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2011

At a glance

  • Drugs Famciclovir; Valaciclovir
  • Indications Herpes genitalis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 16 Jun 2011 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Oct 2008 Results presented at AASLD 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top